Review of icatibant use in the Winnipeg Regional Health Authority

Table 2 Evaluation and treatment of patients prior to icatibant administration

Category	n	Stratification	Count (%)	Expected (%)	p-value (*< 0.05)
Medication history taken	23	NA	23 (100)	NA	1.00
Pertinent positive or negative recorded	12	ACEI	10 (83)	100	0.23
		ARB	3 (25)		0.00*
		NSAID	5 (42)		0.00*
		Estrogen exposure	1 (8)		0.00*
		Family history	1 (8)		0.00*
		Allergies	11 (92)		0.50
Conventional medication administered before icatibant	15	Any diagnosis		NA	NA
		Antihistamines	9 (60)
		Glucocorticoid	11 (73)
		Epinephrine	7 (47)
		C1-INH	4 (27)
		FFP	5 (33)
		HAE (n = 3)
		Antihistamines	0 (0)
		Glucocorticoid	0 (0)
		Epinephrine	0 (0)
		C1-INH	3 (20)
		FFP	0 (0)
		Non-HAE (n = 12)
		Antihistamines	10 (67)
		Glucocorticoid	12 (80)
		Epinephrine	8 (53)
		C1-INH	1 (7)
		FFP	5 (33)
Treatment if signs of mast cell activation	2	Epinephrine	2 (100)	100	1.00
		Antihistamines	2 (100)		1.00
		Glucocorticoids	2 (100)		1.00
Treatment if no signs of mast cell activation	21	Epinephrine	6 (29)	0	0.01*
		Antihistamines	8 (38)		0.00*
		Glucocorticoids	9 (43)		0.00*
CBC before icatibant	23	Any diagnosis	17 (74)	100	0.01*
	10	Prior HAE diagnosis	4 (40)		0.01*
	13	No HAE diagnosis	13 (100)		1.00
Basic chemistry	23	Any diagnosis	12 (52)	100	0.00*
	10	Prior HAE diagnosis	2 (20)		0.00*
	13	No HAE diagnosis	10 (77)		0.11
C4 level	23	Any diagnosis	9 (38)	100	0.00*
	10	Prior HAE diagnosis	4 (40)		0.01*
	13	No HAE diagnosis	5 (38)		0.00*
C1-INH level	23	Any diagnosis	11 (48)	100	0.00*
	10	Prior HAE diagnosis	5 (50)		0.02*
	13	No HAE diagnosis	6 (46)		0.00*
C1-INH function	23	Any diagnosis	7 (30)	100	0.00*
	10	Prior HAE diagnosis	4 (40)		0.01*
	13	No HAE diagnosis	3 (23)		0.00*

ISSN: 1710-1492